Lutetium dotatate was approved by FDA in 2018 for: (A) TB, (B) Neuroendocrine tumours, (C) Crohn's disease, (D) Peptic ulcer
Answer is B. Lutetium (Lu 177) dotatate a radiolabeled somatostatin analogue, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumours in adults.